finance
Wall Street Analysts Adjust Price Targets for Toll Brothers, Bilibili, and Oruka Therapeutics
Analysts from Evercore ISI Group raised the price target for Toll Brothers Inc from $174 to $176 and upgraded the stock rating from In-Line to Outperform. Morgan Stanley increased the price target for Bilibili Inc ADR from $25 to $31 and upgraded it from Equal-Weight to Overweight.
Apr 13, 8:45 AM·2m read1 source
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Wall Street analysts recently updated their outlooks on several stocks, including changes in price targets and ratings for companies in the homebuilding, technology, and biotechnology sectors. These adjustments reflect ongoing evaluations of company performance, market conditions, and future growth prospects. The updates were reported by Benzinga on April 13, 2026.
The firm also upgraded the stock from In-Line to Outperform. 12 on the previous Friday.
U.S. regions. Such rating upgrades can signal analysts' increased confidence in the company's ability to navigate housing market dynamics, including interest rates and demand trends. Investors often monitor these changes for insights into sector health.
adjusted its price target for Bilibili Inc ADR (NASDAQ: BILI) upward from $25 to $31.
The firm upgraded the stock from Equal-Weight to Overweight. 76 on Friday. Bilibili is a Chinese online entertainment platform known for video sharing, live streaming, and anime content. U.S. exchanges, providing international investors access to the company.
This upgrade may indicate positive views on Bilibili's user growth and advertising revenue potential amid competition in the digital media space. These analyst actions occur against a backdrop of global economic factors affecting tech firms, such as regulatory environments in China and shifts in consumer spending.
Further details on other analysts' views are available through Benzinga's ratings page.
increased the price target for Oruka Therapeutics Inc (NASDAQ: ORKA) from $40 to $70. The firm maintained its Buy rating on the stock. 58 on Friday. Oruka Therapeutics is a biotechnology company developing treatments for dermatological conditions.
Maintaining a Buy rating while raising the target suggests sustained optimism about its pipeline and clinical progress. The stock's performance could influence investor interest in biotech innovations targeting skin disorders. Biotech firms like Oruka often face volatility due to clinical trial outcomes and regulatory approvals.
